RATIONALE: Studying samples of blood in the laboratory from young patients with cancer may help doctors learn how carboplatin, cyclophosphamide, and etoposide affect the body and how patients will respond to treatment.
PURPOSE: This laboratory study is evaluating the side effects and how well anticancer drugs work in very young patients with cancer.
Full Title of Study: “Pharmacokinetics and Pharmacogenetics of Anticancer Drugs in Infants and Young Children”
- Study Type: Observational
- Investigate inter-individual variability in the pharmacokinetics of selected anticancer drugs in infants and children age < 2 years on current dosing schedules.
- Compare drug exposures and degree of pharmacokinetic variability in children < 2 years with data obtained from published studies in older children.
- Relate inter-individual variability in pharmacokinetics and drug exposure to clinical toxicity and response.
- Use pharmacokinetic data in conjunction with clinical information obtained following treatment to investigate the suitability of current dosing regimens in infants and young children.
OUTLINE: This is a multicenter study. Patients are stratified according to age in months (0 to 6 vs 6 to 12 vs 12 to 24).
Patients receive carboplatin, cyclophosphamide, or etoposide according to the dosing regimen detailed in the clinical protocol on which the child is being treated.
Blood samples are collected from patients receiving 1 of the 3 drugs by central venous catheter periodically during treatment to measure pharmacokinetics of the specific drug. Additional blood samples are collected for DNA extraction and polymorphism analysis in CYP2B6, CYP2C9, and other metabolizing enzymes in addition to the determination of the genetic variation in multiple drug resistance.
- Drug: carboplatin
- Drug: cyclophosphamide
- Drug: etoposide phosphate
- Genetic: gene expression analysis
- Genetic: polymorphism analysis
- Other: pharmacological study
Clinical Trial Outcome Measures
- Pharmacokinetic parameters
- Pharmacokinetic modelling comparing pharmacokinetic parameters to investigate the key factors involved in determining individual exposures to parent drugs and metabolites
- Influence of pharmacokinetic parameters and genotype for metabolizing enzyme on event-free survival
- Influence of pharmacokinetic parameters and genotype for metabolizing enzyme on toxicity
Participating in This Clinical Trial
- Diagnosis of childhood cancer
- Receiving carboplatin, cyclophosphamide, or etoposide as standard treatment as part of a clinical study at a Children's Cancer and Leukemia Group (CCLG) center
- Not specified
PRIOR CONCURRENT THERAPY:
- Single or double lumen central venous catheter in place
- No concurrent anticonvulsants, azole antifungal agents, or chronic steroid treatment
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: 2 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Children’s Cancer and Leukaemia Group
- Overall Official(s)
- Gareth Veal, Principal Investigator, University of Newcastle Upon-Tyne
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.